Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GeoVax Labs ( (GOVX) ) has provided an announcement.
On July 31, 2025, GeoVax Labs received a deficiency letter from Nasdaq due to its common stock’s closing bid price being below the $1.00 minimum requirement for 30 consecutive business days. The company has until January 27, 2026, to regain compliance. If compliance is not achieved by then, GeoVax may qualify for an additional 180-day period or face potential delisting. The notification does not immediately affect GeoVax’s Nasdaq listing, and the company plans to monitor its stock price and consider options to meet the requirement.
The most recent analyst rating on (GOVX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges, reflected in its low financial performance score. While there are positive developments in vaccine advancements and strategic partnerships, the negative impact of the BARDA contract termination and bearish technical indicators weigh heavily on the overall score.
To see Spark’s full report on GOVX stock, click here.
More about GeoVax Labs
Average Trading Volume: 1,584,511
Technical Sentiment Signal: Sell
Current Market Cap: $18.27M
For detailed information about GOVX stock, go to TipRanks’ Stock Analysis page.